Technical Skills for Weight Loss: Preliminary Data from a Randomized Trial

2002 ◽  
Vol 34 (6) ◽  
pp. 608-615 ◽  
Author(s):  
David L Katz ◽  
Wendy Chan ◽  
Maura Gonzalez ◽  
David Larson ◽  
Haq Nawaz ◽  
...  
2003 ◽  
Vol 27 (12) ◽  
pp. 1500-1506 ◽  
Author(s):  
M-C Yeh ◽  
E Rodriguez ◽  
H Nawaz ◽  
M Gonzalez ◽  
D Nakamoto ◽  
...  

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 2028-P
Author(s):  
JULIE R. LUNDGREN ◽  
ELSE MARIE BLADBJERG ◽  
CHARLOTTE JANUS ◽  
LASSE GLIEMANN ◽  
LISA M. OLSEN ◽  
...  

2021 ◽  
pp. 27-29
Author(s):  
Maitri Hathi ◽  
Sudesh Kumar

Aprevious paper reported the six month comparison of weight loss in overweight and/or obese adults randomly assigned to either a VLCK-diet or LF-diet. To review the one year outcomes between these diets 1year follow-up of a randomized trial on 113 overweight/obese adults with a BMI>25 kg/m2; with no abnormalities were randomly selected. Participants who selected VLCK diet received counseling to restrict carbohydrate intake to <30 gram per day and those who selected LF diet received counseling to restrict caloric intake by 500 calories per day with <30% of calories from fat. Changes in weight, Body Mass Index, Body Fat, and Waist Circumference were measured at intervals of rst, third, sixth and twelfth month of participants who completed the one-year follow-up. Participants on the very-low-carbohydrate diet had lost more weight loss than participants on the conventional low-fat diet at 3months, 6month and but the difference at 12months were signicant. Study conclude that participants on a VLCK-diet had more favorable overall outcomes at 1year than did those on a conventional LF-diet. Weight loss was similar between groups.


10.2196/19053 ◽  
2020 ◽  
Vol 9 (8) ◽  
pp. e19053
Author(s):  
Sean R Locke ◽  
Kaja Falkenhain ◽  
Dylan A Lowe ◽  
Terry Lee ◽  
Joel Singer ◽  
...  

Background Obesity and being overweight are major contributing factors for many diseases. Calorie restricted diets often fail to result in sustained long-term weight loss. Very low–carbohydrate, high-fat ketogenic diets have been suggested to have superior metabolic and weight loss effects. Keyto is a low-cost, highly scalable mobile health (mHealth) app paired with a noninvasive biofeedback tool aimed at facilitating weight loss through a personalized healthy and predominantly plant- and fish-based ketogenic diet. Objective This protocol describes a randomized trial comparing the efficacy of the Keyto mHealth app and device intervention to that of Weight Watchers’ WW app in individuals who are overweight or obese. The primary outcome is weight loss after 12 weeks. Secondary and exploratory outcomes, including metabolic and cardiovascular risk factors, will be assessed at 12, 24, and 48 weeks. Methods A total of 144 participants will be recruited and randomized to either the Keyto program or Weight Watchers program. Study participants will be guided through the study via video conference or phone calls and will undergo a fasting blood analysis performed by a third-party diagnostic lab at weeks 0 and 12 to assess metabolic and cardiovascular risk markers. All participants will be asked to weigh themselves daily on a study-provided Bluetooth-enabled scale. Participants randomized to the Keyto arm will also be asked to measure their breath acetone levels, a measure of ketosis, with the Keyto device 3 times per day. Results Recruitment started in December 2019. Rolling recruitment is expected to be completed by July 2020. Data collection and analysis of the primary intervention phase is expected to be completed in October 2020. The 24- and 48-week follow-ups are expected to be completed in January 2021 and July 2021, respectively. Conclusions This trial will provide high-quality evidence regarding the efficacy of the Keyto weight loss program in individuals who are overweight and obese in a free-living condition. This study also fills a gap by examining the impact of a ketogenic diet emphasizing plant- and fish-based fats on blood lipid profile and cardiovascular disease risk. Trial Registration ClinicalTrials.gov NCT04165707; https://clinicaltrials.gov/ct2/show/NCT04165707. International Registered Report Identifier (IRRID) DERR1-10.2196/19053


Sign in / Sign up

Export Citation Format

Share Document